The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer

Background and purpose: Pancreatic Cancer is an exceptionally fatal disease. However, therapeutic drugs for pancreatic Cancer have presented a serious shortage over the past few decades. Signal transducer and activator of transcription-3 (STAT3) is persistently activated in many human cancers where it promotes tumour development and progression. Natural Products serve as an inexhaustible source of Anticancer drugs. Here, we identified the natural product trienomycin A (TA), an ansamycin Antibiotic, as a potential inhibitor of the STAT3 pathway with potent activity against pancreatic Cancer.

Experimental approach: Effects of trienomycin A on transcriptional activity of STAT3 were assessed by the STAT3-luciferase (STAT3-luc) reporter system. In vitro and in vivo inhibitory activity of TA against pancreatic Cancer made use of molecular docking, surface plasmon resonance (SPR) assay, MTS assay, colony formation assay, transwell migration/invasion assay, flow cytometric analysis, immunofluorescence staining, quantitative real-time polymerase chain reaction (PCR), western blotting, tumour xenograft model, haematoxylin and eosin (H&E) staining and immunohistochemistry.

Key results: Trienomycin A directly bound to STAT3 and inhibited STAT3 (Tyr705) phosphorylation, thus inhibiting the STAT3 pathway. Trienomycin A also inhibited colony formation, proliferation, migration and invasion of pancreatic Cancer cell lines. Trienomycin A also markedly blocked pancreatic tumour growth in vivo. More importantly, trienomycin A did not show obvious toxicity at the effective dose in mice.

Conclusions and implications: Trienomycin A exerted anti-neoplastic activity by suppressing STAT3 activation in pancreatic Cancer. This natural product could be a novel therapeutic candidate for pancreatic Cancer.